Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The syndrome of inappropriate antidiuretic hormone: current and future management options Sherlock M; Thompson CJEur J Endocrinol 2010[Jun]; 162 Suppl 1 (ä): S13-8Hyponatraemia is the commonest electrolyte abnormality, and syndrome of inappropriate antidiuretic hormone (SIADH) is the most frequent underlying pathophysiology. Hyponatraemia is associated with significant morbidity and mortality, and as such appropriate treatment is essential. Treatment options for SIADH include fluid restriction, demeclocycline, urea, frusemide and saline infusion, all of which have their limitations. The introduction of the vasopressin-2 receptor antagonists has allowed clinicians to specifically target the underlying pathophysiology of SIADH. Initial studies have shown good efficacy and safety profiles in the treatment of mild to moderate hyponatraemia. However, studies assessing the efficacy and safety of these agents in acute severe symptomatic hyponatraemia are awaited. Furthermore, the cost of these agents at present may limit their use.|Antidiuretic Hormone Receptor Antagonists[MESH]|Benzazepines/therapeutic use[MESH]|Clinical Trials as Topic/trends[MESH]|Disease Management[MESH]|Forecasting[MESH]|Humans[MESH]|Hyponatremia/etiology/physiopathology/therapy[MESH]|Inappropriate ADH Syndrome/complications/physiopathology/*therapy[MESH]|Receptors, Vasopressin/physiology[MESH]|Tolvaptan[MESH]|Treatment Outcome[MESH] |
